Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8863575 | 1.00 | SLC7A5 (0.40) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL29010766 | 0.93 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL29010817 | 0.93 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL2193200 | 0.93 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL7318989 | 0.93 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL21625553 | 0.93 | SLC7A5 (0.45) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL2184616 | 0.86 | MMP2 (0.39) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL28082201 | 0.86 | MMP2 (0.39) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL6141907 | 0.84 | DPP4 (0.36) | SLC7A5LARS1SCN9AANPEPRNPEP | |
| SCHEMBL6141906 | 0.84 | DPP4 (0.36) | SLC7A5LARS1SCN9AANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951772-B2 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2011-05-31 | — | — | US | claimed |
| US-20090137494-A1 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2009-05-28 | — | — | US | claimed |
| EP-1880737-A1 | Compounds, pharmaceutical composition and diagnostic device comprising same and their use | LA REGION WALLONNE (BE) | 2008-01-23 | — | — | EP | claimed |
| EP-0769967-B1 | CONJUGATES COMPRISING AN ANTITUMOUR AGENT AND THEIR USE | WALLONE REGION (BE) | 2007-12-12 | — | — | EP | claimed |
| US-20060148682-A1 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2006-07-06 | — | — | US | claimed |
| US-7037898-B2 | Drug conguated to a ligand comprising an arm linked to a terminal group through a linkage that prevents intracellular entry of the conjugate, said linkage is selectively cleaved by factors secreted by target cells such as tumors | LAREGION WALLONE (BE) | 2006-05-02 | — | — | US | claimed |
| US-20020160943-A1 | Tumor-activated prodrug compounds and treatment | TROUET ANDRE (BE) | 2002-10-31 | — | — | US | claimed |
| US-6342480-B1 | STABILITY OF COMPOUNDS, TARGET CELLS AND ANTIINFLAMMATORY AGENTS | LA REGION WALLONE (BE) | 2002-01-29 | — | — | US | claimed |
| US-5962216-A | MARKER OR ANTICARCINOGENIC/ANTIINFLAMMATORY/ANTITUMOR AGENT LINKED BY CLEAVABLE SEQUENCE TO STABILIZER OF BETA-ALANINE OR SUCCINIC ACID; TARGETED DELIVERY TO CELL, CLEAVAGE BY CELL SPECIFIC FACTOR FOR ENTRY INTO CELL OR EXPRESSION OF MARKER | LA REGION WALLONNE (BE) | 1999-10-05 | — | — | US | claimed |
| EP-0769967-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND DIAGNOSTIC DEVICE COMPRISING SAME AND THEIR USE | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 1997-05-02 | — | — | EP | claimed |
| WO-1996005863-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND DIAGNOSTIC DEVICE COMPRISING SAME AND THEIR USE | LA REGION WALLONNE (BE) | 1996-02-29 | — | — | WO | claimed |
| JP-1040499-A | — | — | None | — | — | JP | disclosed |
| US-7951772-B2 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090137494-A1 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2009-05-28 | — | — | US | disclosed |
| US-7390629-B2 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2008-06-24 | — | — | US | disclosed |
| EP-0279862-B1 | CYTOCIDAL ANTIBODY COMPLEX AND PROCESS FOR ITS PREPARATION | TEIJIN LTD (JP) | 1993-11-03 | — | — | EP | disclosed |
| US-5030719-A | A folic acid-antagonistic folic acid analogue bound to an antibody through an oligopeptide; antitumor and -carcinogenic agents | TEIJIN LIMITED (JP) | 1991-07-09 | — | — | US | disclosed |
| JP-S6440499-A | FOLIC ACID-ANALOG DERIVATIVE AND PRODUCTION THEREOF | TEIJIN LTD | 1989-02-10 | — | — | JP | disclosed |
| EP-0279862-A1 | CYTOCIDAL ANTIBODY COMPLEX AND PROCESS FOR ITS PREPARATION | TEIJIN LIMITED (JP) | 1988-08-31 | — | — | EP | disclosed |
| JP-S06440499-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148682-A1 | Tumor-activated prodrug compounds and treatment | GZMB, B2M, TNFSF10 | SLC7A5 1736/4885LARS1 4135/4885SCN9A 4270/4885 |
| US-20090137494-A1 | Tumor-activated prodrug compounds and treatment | GZMB, B2M, TNFSF10 | SLC7A5 1736/4885LARS1 4135/4885SCN9A 4270/4885 |
| US-20020160943-A1 | Tumor-activated prodrug compounds and treatment | B2M, GZMB, TNFSF11 | SLC7A5 1163/4885LARS1 4301/4885SCN9A 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.